Our results showed that the effects of Aβ plaque clearance and the anti-cognitive impairment effects induced with TMAS treatment were significantly greater than those induced with TUS and sham treatments, and the improved performance of TMAS was mediated through microglial functions via the PI3K-AKT signaling pathway. The gene discussed is AKT1; the disease is Cognitive impairment.